Respiratory Technology, Woolcock Institute of Medical Research & Discipline of Pharmacology, Sydney Medical School, Sydney University, NSW 2037, Australia.
Faculty of Pharmacy, Umm Al Qura University, Makkah, Saudi Arabia.
Nanomedicine (Lond). 2017 Oct;12(20):2471-2485. doi: 10.2217/nnm-2017-0188. Epub 2017 Sep 20.
Current inhaled treatments are not adequate to treat all lung diseases. In this study, a promising nanotechnology has been developed to deliver a potential anti-inflammatory and muco-inhibitory compound, simvastatin, for treatment of inflammatory lung diseases via inhalation.
MATERIALS & METHODS: Simvastatin nanoparticles (SV-NPs) encapsulated with poly(lactic-co-glycolic) acid were fabricated using the solvent and anti-solvent precipitation method.
SV-NPs were found to be stable up to 9 months at 4°C in a freeze-dried form prior to reconstitution. The amount of mucus produced was significantly reduced after SV-NPs treatment on inflammation epithelial cell models and were effective in suppressing the proinflammatory marker expression.
This study suggests that SV-NPs nebulization could potentially be used for the treatment of chronic pulmonary diseases.
目前的吸入疗法不足以治疗所有肺部疾病。在这项研究中，开发了一种有前途的纳米技术，通过吸入将一种有潜力的抗炎和粘液抑制化合物辛伐他汀递送至肺部以治疗炎症性肺部疾病。
使用溶剂和反溶剂沉淀法制备包封有聚（乳酸-共-乙醇酸）的辛伐他汀纳米颗粒（SV-NPs）。
SV-NPs 在冻干形式下在 4°C 下稳定长达 9 个月，然后再进行重构。在炎症上皮细胞模型中，SV-NPs 处理后产生的粘液量明显减少，并且能够有效抑制促炎标志物的表达。
本研究表明，SV-NPs 雾化可能可用于治疗慢性肺部疾病。
